Health-State Utilities and Quality of Life in Hepatitis C Patients
about
Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United StatesCost-utility analysis of nonalcoholic steatohepatitis screening.Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network.The hepatitis C cascade of care: identifying priorities to improve clinical outcomesCost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in IndiaFactors influencing health-related quality of life in chronic liver disease.Reducing infection transmission in solid organ transplantation through donor nucleic acid testing: a cost-effectiveness analysisCost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men.Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling studyCost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programsAchieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefitsClinical impact of treatment timing for chronic hepatitis C infection: a decision modelEstimation of utilities for chronic hepatitis C from SF-36 scores.Chronic liver disease questionnaire: translation and validation in ThaisEstimating cost-effectiveness associated with all-oral regimen for chronic hepatitis C in China.Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysisHealth-state utilities in liver disease: a systematic review.Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C.Health-Related Quality of Life in HIV-Infected and At-Risk Women: The Impact of Illicit Drug Use and Hepatitis C on a Community Preference Weighted Measure.Tobacco and other factors have a negative impact on quality of life in hepatitis C patients.Pioglitazone and vitamin E for nonalcoholic steatohepatitis: a cost utility analysis.Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis.Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States.The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States.Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list.Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of Egypt.Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal.Quality-of-life tradeoffs for hepatitis C treatment: do patients and providers agree?Cost-effectiveness of using a gene expression profiling test to aid in identifying the primary tumour in patients with cancer of unknown primary.Cost-effectiveness of pegylated IFN-alpha2b and -2a and ribavirin for chronic hepatitis C treatment.Effectiveness and safety of daclatasvir plus asunaprevir for patients with hepatitis C virus genotype 1b aged 75 years and over with or without cirrhosis.Changes in quality of life, healthcare use, and substance use in HIV/hepatitis C coinfected patients after hepatitis C therapy: a prospective cohort study.The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.Simeprevir added to peginterferon and ribavirin lessens time with fatigue, depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST-1, QUESDisease burden of chronic hepatitis C among immigrants in Canada.Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting.The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States.Cost-effectiveness analysis of antiviral treatment in liver transplant recipients with HCV infection.
P2860
Q28488762-76E0EE93-4A6A-4A97-9E53-D277D7C6D1BBQ30385602-51573F05-E2CB-4A6D-87A8-C767D25998A3Q33444032-5BDC5D2B-D873-4DCE-928C-65B59B16E3D4Q33632459-180C637E-B5DD-46D4-AEAC-DD5A72F6C13BQ33698956-A3403FE4-28D4-4AA4-B40A-43BE72DE8D14Q33866690-1893E35D-AA1B-4A3B-BD4B-D7CE79D2E5CFQ33882186-6114AC9E-7FA1-412C-ACAD-BBF541A0E9D5Q34227450-76163362-4C6E-489C-8BCD-CFD8E8D20557Q34690368-253164AE-1FFE-4684-BB0E-01175A45812BQ34735072-B941110C-3DD3-4E36-8B5F-67856285F7ABQ34987336-BB0F5EB1-C07C-470D-B46D-04B10FE1573EQ35889164-BDF7C74C-366D-4140-81E3-A5E9D92A5645Q36060018-BB51D473-70EF-409C-8DBC-F6C4E349FCD1Q36065914-EB3754EB-4462-447A-88D9-9F5BEBC38C4DQ36336005-A4DFC272-8C08-4C34-A9F4-06D619C63372Q36608549-3F00462C-C70E-4E9B-A0F5-D21B300A3B12Q37142994-E0EE4E56-55F8-4AD5-B57F-356F3862EF0CQ37536874-9D55DC66-AFEF-4750-B359-FEC720194516Q37693067-64A3FE3C-1728-4466-9056-9D0546830D90Q37781103-FF63D5CA-3904-4331-8DB2-AFB4E749DB2FQ38019467-62AB59BB-6DBA-428D-8D61-A6E864F0D879Q38932103-069B66F9-4EB0-40F5-938A-0DE779631BADQ39025577-F8ED0B3B-3229-46C1-8323-0F8876938F90Q39102936-7E3DCB88-D634-4C62-8540-3B2516DAC3F7Q39137372-1EBEBB40-51D4-440F-A268-79442DF04E49Q39139767-8B28806D-8441-45A4-AB99-10C4FD49D86FQ39153261-E695603B-BAB2-4B0D-A869-B85F372EA755Q39315202-FE5BAC8C-589C-4226-91A5-011E3FBC8899Q39478177-B85D7817-9C2E-404D-ABB0-CABA8DBA1435Q39839514-A22323A1-B485-4197-9E0D-C59CA7A69099Q39885004-B03981C5-EF8E-47C6-8D9D-DF1D126266E3Q40479083-0447AD65-C8CA-446D-BE7B-1A6DE52AF7F7Q40689148-686A51F1-C423-4523-8608-09D81C21C6F6Q40942161-72A1901B-3577-406A-870C-DD9F633F55BFQ41207230-81D070C3-1BF2-4DF3-BDA7-667050F99485Q41610311-F8B16079-1E31-4359-9893-5951C22E7630Q41642114-F0724A9A-543D-44CE-8938-AA3841B93D67Q42706768-20AED18A-98A0-4239-B1A4-DBDCD05AFD93Q42988978-56A69E8C-70FE-4BF2-838B-78ED4F6CB4DCQ42990378-0604FE15-EFD9-42AE-A176-81B2709C358E
P2860
Health-State Utilities and Quality of Life in Hepatitis C Patients
description
article
@en
im März 2003 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в березні 2003
@uk
name
Health-State Utilities and Quality of Life in Hepatitis C Patients
@en
Health-State Utilities and Quality of Life in Hepatitis C Patients
@nl
type
label
Health-State Utilities and Quality of Life in Hepatitis C Patients
@en
Health-State Utilities and Quality of Life in Hepatitis C Patients
@nl
prefLabel
Health-State Utilities and Quality of Life in Hepatitis C Patients
@en
Health-State Utilities and Quality of Life in Hepatitis C Patients
@nl
P2093
P2860
P1476
Health-State Utilities and Quality of Life in Hepatitis C Patients
@en
P2093
Anar Gulamhussein
Christopher A.K.Y. Chong
E.Jenny Heathcote
Gary Naglie
Morris Sherman
P2860
P304
P356
10.1111/J.1572-0241.2003.07332.X
P407
P50
P577
2003-03-01T00:00:00Z